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Han klämde lite på honom och lyssnade på hans hjärta. Det var ju inget fel, det 
visste han. Hjärtat pumpade. Lungorna höjde och sänkte bröstet. Men han 
tyckte att nån borde röra vid honom.*  
ur Händelser vid vatten av Kerstin Ekman 
 
 
 
 
 
 
 
 
 
 
 
.  
 
 
 
 
                
To my parents, Karin and Åke 
 
 
 
 
 
 
* He touched him a little and listened to his heart. Obviously, nothing was wrong, he knew 
that. The heart was working. The lungs raised and lowered the chest. But he thought that 
someone should touch him. 
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ABSTRACT 
Background: Recurrent abdominal pain (RAP) due to an abdominal pain-related functional 
gastrointestinal disorder (ap-FGID) is one of the most common disorders of childhood and it 
accounts for much suffering and many healthcare efforts. Both school absence and parental 
work absence can be considerable when young children are affected. The aetiology of ap-
FGID is regarded multifactorial, where the bidirectional gut-brain axis is thought to have a 
central role, involving gut microflora and psychosocial events. The biopsychosocial model 
seems superior to standard medical care when treating children with ap-FGID. The current 
terminology adheres to the symptom-based Rome criteria of different ap-FGIDs, most 
recently updated 2016 in Rome IV. There are scarce evaluations of the accuracy of the 
paediatric Rome diagnostic criteria and suggested alarm symptoms in diagnosing ap-FGID. 
Methods: This thesis was founded on four studies, based on two population-based birth 
cohorts and one clinical study.  
In study I, 258 children 4-17 years old seeking care for gastrointestinal complaints were 
evaluated. Validated Rome III based patient-administered symptom questionnaires were 
filled in at the initial visit, blinded to the clinician. One year after inclusion a reference 
diagnose was set through review of electronic records. The sensitivity and specificity of the 
Rome III criteria for ap-FGID combined with selected alarm symptoms and/or laboratory 
tests were explored in four-field tables.  
Study II was based on a population-based birth cohort, BAMSE (n=4089). The association 
between antibiotic use and RAP at 12 years was explored. Information on early childhood 
antibiotic use during the first two years of life was based on parental questionnaires. 
Antibiotic use during the three years before gastrointestinal evaluation at 12 years of age was 
derived from the Swedish prescribed drug register. RAP was defined as monthly abdominal 
pain according to questionnaire self-report.  
Study III was performed in a subset of the lifestyle birth cohort ALADDIN (n=470). Children 
growing up in families of different lifestyles were explored regarding ap-FGID at five years 
of age. The three different, predefined family lifestyles were anthroposophic, partly 
anthroposophic and non-anthroposophic and classified through parental questionnaires. The 
Rome III-defined ap-FGIDs irritable bowel syndrome, functional dyspepsia and functional 
abdominal pain were assessed at five years through questionnaires and telephone interviews.  
Study IV was based on the BAMSE cohort. RAP was measured on three time points: in early 
childhood, containing pooled data from 12 and 24 months, at 12 years and at 16 years. In 
early childhood RAP was defined as parental report of abdominal pain during the previous 6 
and 12 months respectively. Questionnaire data at 12 and 16 years were self-reported, and 
RAP defined as weekly abdominal pain. At 16 years the questionnaires also allowed for 
definitions according to Rome III for ap-FGID, irritable bowel syndrome, functional 
dyspepsia and functional abdominal pain. Binominal generalised linear model with log link 
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was used to assess the association expressed as relative risk, between RAP in early childhood 
or at 12 years and RAP at 12 and 16 years, and any ap-FGID and irritable bowel syndrome at 
16 years.  
Results: In study I we found that Rome III criteria for ap-FGID in combination with absence 
of any alarm symptoms had high specificity (0.90) but very low sensitivity (0.15) in 
diagnosing children with ap-FGID. Alarm symptoms were equally common (81 % in total 
cohort) regardless of the cause of gastrointestinal complaints.  
In study II we found no evidence that antibiotic use was associated with monthly RAP at 12 
years of age.  
The lifestyle study (III) revealed an increased risk of ap-FGID at five years in children 
growing up in families with a partly anthroposophic lifestyle, adjusted Odds Ratio 2.6 (95 % 
confidence interval: 1.1-5.9). No specific factor of the anthroposophic lifestyle could be 
identified as bearing this increased risk.  
The prognosis study (IV) showed that most children with RAP in early childhood were not 
affected at 12 years of age, adjusted Relative Risk (RR) 1.7 (95 % CI: 0.9-3.0). Most children 
with RAP at 12 years of age were not affected at 16 years but had an increased risk of RAP at 
16 years, adjusted RR 2.1 (95 % CI: 1.7-2.7), and of ap-FGID at 16 years of age, adjusted RR 
2.5 (95 % CI: 1.8-3.4). In the cohort 33 % of children had RAP at least once between one and 
16 years of age. 
Conclusion: The Rome III criteria combined with absent alarm symptoms classified very few 
children with ap-FGID. When criteria were fulfilled, and alarm symptoms negative in 
children with gastrointestinal complaints, the risk of an organic disease was low. Antibiotic 
use was not a major risk factor for RAP. Children in families with distinct differences in 
family lifestyle had a two-fold increased risk of ap-FGID at five years, but mechanisms are 
unclear. We speculate in differences in childhood coping development. The prognosis in RAP 
was benign, with most children growing out of their symptoms. The increased risk of 
persistent RAP between 12 and 16 years that was found, can be useful in guiding clinicians 
on how to follow up children with ap-FGID.  
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1 INTRODUCTION 
 
Recurrent abdominal pain (RAP) is one of the most common medical complaints during 
childhood and adolescence 1-3. RAP is prevalent in several clinical settings and often 
accompanied by substantial family worries and parental work absence 4, 5. Some children 
and adolescents are exposed to a lot of costly and invasive medical investigations with 
typically scarce findings and small benefit for the child 6, 7. If a specific diagnosis of the 
pain cannot be established it may capture the child and family in repeated and new 
investigations, with possible negative effects on the prognosis of pain, illness behaviour and 
disability 8. 
The clinical presentation of RAP shows large variations. The frequency and duration of the 
pain attacks and the length of periods with pain are highly variable. There are also large 
differences concerning suffering and impact on everyday life such as school absence.  
The aetiology of childhood RAP is also varied, and the cause is considered multifactorial.  
The currently most customary approach to functional gastrointestinal disorders is the 
“biopsychosocial model” 9. This model implies that symptoms are a result of the 
bidirectional interaction between physiological processes and psychosocial influences 10. 
Treatment according to the biopsychosocial model relies on validation, family education 
and reassessment, with the aim of symptom reduction and return to normal activities 9. 
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2 BACKGROUND 
2.1 DEFINITIONS 
The large variety of symptoms and aetiological factors related to childhood recurrent 
abdominal pain is reflected in many different definitions intending to describe the 
phenomenon. The concept of RAP has already been introduced and will be described more 
in detail below. Moreover, the Rome criteria will be described in detail. 
2.1.1 Recurrent abdominal pain (RAP) 
The term RAP is today commonly used as a description and not as a diagnosis, a childhood 
condition with long-lasting, intermittent or constant abdominal pain (Table 1). Apley and 
Naish, two English paediatricians, published a classical, often cited study in 1958 on 1000 
children with ‘recurrent abdominal pain’, thereby introducing this concept into the scientific 
literature 11. RAP was defined as ≥3 bouts of abdominal pain severe enough to interfere with 
activities, appearing in a period of ≥3 months. The cause of pain was not considered, i.e. 
functional and organic RAP were not separated, which is a major difference between their 
definition and later terminology according to the Rome foundation. In 1999, von Baeyer 
proposed a two-stage approach to the classification of children with RAP, where the second 
step referred to the cause of pain 12. The use of the word RAP is prevalent in literature and 
scientific papers, but it does not always adhere strictly to the Apley & Naish definition from 
1958. Approximately 90 % of paediatric cases with RAP seem to have a mainly functional 
background 3. Examples of other causes of RAP in childhood are constipation, cow’s milk 
protein intolerance, celiac disease (CD), esophagitis, inflammatory bowel disease (IBD), 
endometriosis (girls), duodenal ulcer and lactose intolerance.  
Health care visits for paediatric acute abdominal pain are common in both primary care and 
emergency care settings 13. Acute abdominal pain is also frequently caused by an abdominal 
pain-related functional gastrointestinal disorder (ap-FGID) but a number of other diagnoses 
should be considered. In a large academic primary care population of children ≥4 years of 
age, acute and chronic constipation was the most common cause of acute abdominal pain 14. 
In the same study, a surgical cause was present in 2 % of subjects and in 19 % the cause for 
the acute abdominal pain remained unknown 14. The differential diagnoses of acute 
abdominal pain in children varies greatly with the child’s age and can be described as 
surgical, nonsurgical or extra-abdominal 15. Examples of surgical causes are acute 
appendicitis and ovarian or testicular torsion. Non-surgical causes can be gastroenteritis, 
constipation, urinary tract infection or Henoch-Schönlein purpura. Extra-abdominal reasons 
for acute abdominal pain in children can be pneumonia, otitis media and diabetes mellitus 15.  
 
 
 
 
  
 
Table 1. Distinction between RAP and ap-FGID in thesis 
RAP childhood condition of long-lasting, intermittent or constant abdominal 
pain, regardless of the cause but often medically un-explained  
ap-FGID scientific description of non-organic recurrent abdominal pain, that is 
pain of functional origin, according to Rome III criteria 
 
2.1.2 The Rome criteria 
The Rome criteria are established, international classifications of both children and adults 
with functional gastrointestinal disorders (FGID) 16-18. These criteria are intended for clinical 
as well as scientific purposes. The Rome foundation is an international, non-profit 
organisation with the goal to improve the lives of people with FGIDs, through research and 
education (https://theromefoundation.org/).  
The Rome foundation has designed detailed questionnaires to enable descriptions and 
classifications of the different disorders, based on patients’ symptom descriptions. There is a 
special, updated version for children, the Rome IV Diagnostic Questionnaire on Paediatric 
Functional Gastrointestinal Disorders (R4PDQ). The previous Rome III Questionnaire on 
Paediatric Gastrointestinal Symptoms (QPGS-RIII) has been translated to several languages 
and validated in different settings 19, 20. 
At present, most research on RAP is based on the Rome criteria, that are regularly updated 
(Table 2). The Rome I criteria were defined for adults only. The first version of paediatric 
Rome criteria, Rome II, was published in 1999, using classifications according to main 
complaints, not according to the affected organ system 16. The definitions of the different 
versions of the Rome criteria are presented in Table 2 which also, for comparisons, presents 
the Apley & Naish definition of RAP. The required symptom duration for ap-FGIDs in the 
Rome II-version was three months or more, except for abdominal migraine. In the updated 
Rome III-version this requirement was changed to a pain frequency of once weekly for two 
months or more 17, 20. FGID can be divided in abdominal pain-related conditions (ap-FGID), 
and conditions where pain is not dominating. The ap-FGIDs are functional dyspepsia (FD), 
irritable bowel syndrome (IBS), functional abdominal pain (FAP) and abdominal migraine. In 
Rome III, all four have the additional diagnostic criteria of “no evidence of an inflammatory, 
anatomic, metabolic, or neoplastic process considered that explains the subject’s symptoms”. 
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Table 2. CLASSIFICATION OF RECURRENT ABDOMINAL PAIN DISORDERS 
Apley/Naish11 
1958 
Rome II16 
1999 
Rome III17  
2006 
Rome IV18  
2016 
RAP: recurrent 
abdominal pain 
 
ap-FGID: abdominal 
pain-related functional 
gastrointestinal 
disorders 
FAPD: functional 
abdominal pain 
disorders 
1. 3 episodes of 
abdominal pain  
 
 
 
2. During a period 
of 3 months  
 
3. Pain severe 
enough to 
affect activities 
 
 
1. Persistent/recurrent 
pain/discomfort  12 
weeks 
 
 
2. Within the preceding 
12 months  
 
3. No evidence of an 
organic disease 
 
1. Persistent/recurrent 
pain/discomfort 
once every week 
 
 
2. 2 months before 
diagnosis 
 
3. No evidence of an 
inflammatory, 
anatomic, metabolic, 
or neoplastic 
process that explain 
the symptoms 
1. Symptoms of 
pain/postprandial 
fullness/early 
satiation 4 days/ 
month  
2. 2 months before 
diagnosis 
 
3. After appropriate 
medical evaluation, 
the symptoms 
cannot be 
attributed to 
another medical 
condition 
Phenotypes: FD, IBS, FAP FD, IBS, FAP, FAPS FD, IBS, FAP-NOS 
FD, functional dyspepsia; FAP, functional abdominal pain; FAP-NOS, functional abdominal pain-not 
otherwise specified; FAPS, functional abdominal pain syndrome; IBS, irritable bowel syndrome 
 
 
FD is defined as persistent/recurrent pain or discomfort centred in the upper abdomen, not 
associated with defecation or a change in stool frequency or stool form. IBS is defined as 
abdominal discomfort or pain associated with two or more of the following symptoms: 
improvement with defecation, onset of a change in stool frequency and/or onset of change in 
form of stool. FAP is defined as episodic or continuous abdominal pain and insufficient 
criteria for other FGID. FD, IBS and FAP require that criteria are fulfilled at least once per 
week for at least two months before diagnosis. Abdominal migraine, not part of the thesis, is 
  
defined as paroxysmal episodes of intense, acute periumbilical pain that interferes with 
normal activities, lasting for one hour or more. It has a required occurrence of two or more 
episodes in the preceding 12 months, intervened by periods of usual health. The pain is 
associated with two or more of: anorexia, nausea, vomiting, headache, photophobia and 
pallor (Table 3). 
The studies of this thesis were conceived before the introduction of Rome IV criteria in 2016, 
and therefore the terminology of Rome III will be used consistently. Out of general interest 
these up-dated criteria will be presented briefly below. The paediatric Rome IV criteria are 
divided in three parts: functional nausea and vomiting disorders, functional abdominal pain 
disorders (FAPD) and functional defecation disorders. The Rome III concept of ap-FGID was 
replaced by Functional Abdominal Pain Disorders (FAPD) 18. A new term, "functional 
abdominal pain−not otherwise specified" (FAP-NOS) was introduced to describe children 
with recurrent abdominal pain that is neither IBS, nor Functional dyspepsia (FD) nor 
abdominal migraine. FAP-NOS, IBS and FD all have in common that “abdominal pain must 
appear at least four times/month during two months” prior to diagnosis, in addition to the 
statement that “after appropriate evaluation, the symptoms cannot be fully explained by 
another medical condition”. A modification of the words that describe the abdominal 
sensation was adopted, when abdominal discomfort in IBS and FAP of Rome III was 
replaced by abdominal pain in Rome IV. The wordings postprandial fullness and early 
satiation, not obligate abdominal pain, are used to describe FD in Rome IV.  
The word “functional” in FGID is unspecific but relates to symptoms supposedly caused by 
the normal “function” of the gastro-intestinal tract. Apparently, the term has been under 
debate and with the Rome IV criteria in 2016, a new term has been established in the adult 
criteria: Disorders of the Gut Brain Interaction (DGBI)21, 22. With this expression, which will 
be described in detail in 2.2.2. Gut-brain axis, the Rome foundation incorporates the plausible 
aetiology of the disorders within the Rome terminology.  
 
2.1.3 A positive diagnosis 
The adult gastroenterologist Manning stated that a more careful history taking could prevent 
unnecessary investigations and increase diagnostic confidence in patients with RAP. In 1978 
he suggested that irritable bowel syndrome (IBS) should be regarded as a positive diagnosis, 
based on four selected criteria: abdominal distension, pain relief with bowel action, more 
frequent stools with the onset of pain and looser stools with the onset of pain. The presence of 
three or four of these criteria in the adults of the study predicted IBS with a sensitivity of 62 
% and a specificity of 85 % 23. In the Rome III statement, the precursor of Rome IV, the 
additional criteria to symptom descriptions was that there should be ”no evidence of organic 
disease”. In Rome IV, this statement was modified.  It was now claimed that an “appropriate 
medical evaluation” should be made after the symptom description, without pointing out 
certain tests 18. So, in line with Manning’s thoughts about a careful history taking, the Rome 
committee of 2016 seems to emphasise that functional diagnoses are clinical, and not 
dependent on tests and investigations.  
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Table 3. ROME III ABDOMINAL PAIN-RELATED FUNCTIONAL 
GASTROINTESTINAL DISORDERS  
FUNCTIONAL DYSPEPSIA (FD) 
1. Persistent or recurrent pain or discomfort centred in the upper abdomen                      
(above the umbilicus) 
2. Not relieved by defecation or associated with the onset of a change in stool frequency or 
stool form  
IRRITABLE BOWEL SYNDROME (IBS) 
1. Abdominal discomfort or pain associated with two or more of the following at least                   
25 % of the time: 
a. Improved with defecation 
b. Onset associated with a change in frequency of stool 
c. Onset associated with a change in form (appearance) of stool 
FUNCTIONAL ABDOMINAL PAIN (FAP) 
1. Episodic or continuous abdominal pain 
2. Insufficient criteria for other FGID 
Obligate criteria in FD, IBS and FAP: 
• Criteria fulfilled at least once per week for at least two months before diagnosis 
• All of the numbered criteria must be fulfilled  
• No evidence of an inflammatory, anatomic, metabolic, or neoplastic process that 
explains the subject’s symptoms 
ABDOMINAL MIGRAINE (not investigated in thesis) 
 
Criteria fulfilled two or more times in the preceding 12 months: 
1. Paroxysmal episodes of intense, acute periumbilical pain that lasts for one hour or more 
2. Intervening periods of usual health lasting weeks to months 
3. The pain interferes with normal activities 
4. The pain is associated with two or more of the following: anorexia, nausea, vomiting, 
headache, photophobia, pallor 
Source: Gastroenterology. 2016 Feb 15. pii: S0016-5085(16)00181-5.  
doi: 10.1053/j.gastro.2016.02.015.  
 
  
2.1.4 Alarm symptoms 
The Rome IV statement that after “appropriate evaluation, the symptoms cannot be fully 
explained by another medical condition” is not very helpful in providing the paediatrician 
with instructions on what investigations should be performed in the child with RAP. One 
complementary diagnostic approach is the use of so called alarm symptoms, also called red 
flags 1, 18. These are signs, symptoms and pathologic laboratory tests that, when present, 
decreases the probability of a functional diagnosis (Table 4). The concept of alarm symptoms 
is poorly defined, and definitions vary between publications and with patient’s age. In adult 
gastroenterology efforts have been made to validate alarm symptoms for different definitions 
of FGID 24. The alarm symptom antibiotic use appears in adult but not in paediatric studies. 
The number of alarm symptoms registered varies from 4 to 10 between studies. In most 
studies alarm symptoms are dichotomous (“yes” or “no”), but occasionally the symptom 
should have been present in ≥ 25 % of the pain attacks. The accuracy of each method depends 
not only on the questionnaire/definition used, but also on the setting and whether subjects 
with FGID are compared with healthy controls or subjects with organic disease. Accordingly, 
the prevalence of alarm symptoms shows great variations across studies 25-28.  
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2.2 AETIOLOGY  
Most evidence suggests a multifactorial aetiology of paediatric FGID and ap-FGID. The 
amount of research on risk factors for ap-FGID is larger in adults than in children and results 
are often contradictive 29. The biopsychosocial model has dominated research on childhood 
ap-FGID in the last decade 30. A biopsychosocial perspective refers to the interaction between 
biologic and/or physiologic events and psychosocial factors, through the gut-brain axis, 
which will be discussed below 31-34. Some specific childhood medical events like asphyxia, 
perinatal airway suction, pyloric stenosis, hypersensitivity to cow’s milk protein and Henoch-
Schönlein purpura have all been linked to FGID and ap-FGID in single studies 35-37. 
However, not all factors shown to be associated with ap-FGID are possible to study with a 
prospective design. Thus, the cause and effect relationship is difficult to evaluate. 
The aetiological factors that will be discussed below are: genetic predisposition, microbiota 
and gut-brain axis, inflammation, visceral hypersensitivity and motility, lifestyle and coping 
style, food, psychosocial factors and stress, exposure to adversities. 
  
2.2.1 Genetic predisposition 
Visceral pain in relation to genetics has been described, indicating genetic variations in ion 
channels, barrier function and neurotransmitters in IBS patients 38. A Norwegian study 
supported a genetic component in IBS, with monozygotic twins having 17 % concordance 
rate in IBS. In the same study it was also reported that having a parent with IBS was an 
independent predictor of IBS, stronger than having a twin with IBS. Thus, social learning had 
an equal or stronger influence than the genetics 39. In a recent study on Rome IV diagnostic 
criteria, the mothers of 4-18-year olds completed online questionnaires. Children whose 
parents qualified for a FGID were more likely to qualify for a FGID themselves 40. In a study 
from the BAMSE birth cohort, (not part of this thesis) a genetic variation at the NPSR1 locus, 
Figure 1. Pathophysiology of functional abdominal pain disorders. Modified after 
Gastroenterology 2016;150:1456–1468 
CHILD/ADOLESCENT 
  
which encodes the receptor for neuropeptide S (NPS), was associated to RAP in 12-year-old 
children 41. The possible mechanisms of this genetic variation may act through increased 
expression of neuropeptides, thus modulating gut sensory and motor function.  
2.2.2 Microbiota and the gut-brain axis 
The intestinal canal is sterile upon birth but is rapidly colonised during the first year 42, 43. The 
developing childhood microbiota has the potential to modulate the immune system and to 
ensure tolerance to foods 44. Antibiotic treatment, diet and mode of delivery influence the gut 
microflora (Figure 2) 43, 45. A bacterial gastroenteritis confers an increased risk of IBS, which 
will be covered in the next section (2.2.3 Inflammation) 46. This association leads to the 
hypothesis that FGID depends on a disturbed microbiota. The amount of research on 
microbiota and FGID has increased rapidly during the last decades, but most studies have 
been performed in adult populations. Some paediatric studies support that an altered gut 
microbiota is involved in paediatric IBS, but no single bacterial strain or genera has been 
identified as a single cause 47-49. Bacterial diversity, that is a microflora composed of many 
different bacterial strains, appears to be desirable in many aspects 50.  
The gastrointestinal tract from mouth to anus contains an immense number of bacteria and a 
vast immune system along with enteric innervation. These three systems; microbiota, the 
enteric immune system and the enteric nerve system exist alongside and have an intense 
interaction. The biochemical signalling between the gastrointestinal tract and the central 
nerve system is called the gut brain axis 51. In the central nervous system, these processes 
supposedly interfere with pain experiences 52. Still, the cause-effect between microbiota and 
FGID is not surely established, since it has not been studied prospectively in humans. Animal 
research supports that microbiota has an impact on the mind and behaviour 53, 54. The 
mechanisms in the gut-brain-axis is supposedly caused partly by dysbiosis inducing an 
inflammatory response, thus interacting with the enteric nerve system 32, 33. Studies on 
germfree animals have revealed that these animals show an exaggerated hypothalamic 
response to psychological stress, and that this increased response can be normalised with gut 
colonisation 55.  
2.2.3 Inflammation 
The strongest known risk factor for developing IBS is a previous episode of gastroenteritis. 
Associated factors that increase the risk are severity of initial illness, female sex and adverse 
psychological factors 46. The magnitude of the increased risk for childhood IBS after 
gastroenteritis has been demonstrated to be twofold, or with a shorter follow-up time after the 
infection, as high as three to four-fold 56-58. A childhood salmonella or giardia gastroenteritis 
in smaller studies has been associated to a three-fold increased risk of adult IBS, up to a 
decade after the episode 59-61. Increased prevalence in functional dyspepsia (FD) after a viral 
gastroenteritis has been demonstrated in adult but not in paediatric studies 59, 62.  
The postulated mechanism of low-grade inflammation in ap-FGID is seen in different signs 
of immune dysregulation. Differences have been found in small studies regarding 
gastrointestinal permeability, peripheral blood cytokines and inflammatory cell counts of 
intestinal biopsies in IBS (children) and in FD (adults), but these signs of inflammation are 
not macroscopically visible 33, 63-69. Neither blood nor faecal samples from ap-FGID patients 
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display signs of general inflammation. Calprotectin, a calcium- and zinc-binding protein 
abundant in neutrophils, measured in faecal samples is widely used clinically in the diagnosis 
and management of inflammatory bowel diseases 70. Childhood FGID was not related to 
elevated levels of calprotectin in a few studies, thus contradicting a significant inflammatory 
component in ap-FGID 71-73. Calprotectin is a useful tool in discriminating FGID and IBD in 
children. A meta-analysis showed that adding calprotectin to the diagnostic workup of 
paediatric patients with chronic gastrointestinal symptoms improved the diagnostic efficacy 
of IBD 70.  
2.2.4 Visceral hypersensitivity and motility 
Physiological changes in the gastrointestinal tract usually do not induce pain. Visceral 
hyperalgesia in ap-FGID has been demonstrated in many controlled studies 74-76. Children 
with ap-FGID had significantly lower thresholds than comparisons for both sensation and 
pain in response to rectal as well as gastric distension 76. Motility disturbances presenting as 
delayed gastric emptying and abnormal antral motility have been found in children and linked 
to symptom severity of ap-FGIDs but also to the exposure to previous emotionally stressful 
events 77, 78. Experimental data supports that early life pain or stress can induce impaired 
stress response and altered descending neuronal inhibitory control, with possible subsequent 
visceral hypersensitivity 79. The role of serotonin in children with FGID is explored in 
intestinal biopsies which have revealed a higher serotonin content in IBS but not in FD, 
indicating that serotonin signalling plays a role in paediatric IBS pathogenesis 68, 80.   
2.2.5 Lifestyle and coping style  
 
Lifestyle characteristics such as diet and stress may induce epigenetic changes that may in 
turn be key factors in the development of chronic pain 81. This can occur for example as DNA 
methylation or acetylation, without demonstrable changes in the genetic sequence 81. The rise 
in incidence of obesity, cardiovascular disease and stress-related disorders are commonly 
regarded as associated to modern lifestyle and society’s affluence 82. The increased 
prevalence of allergies and other immune-related disorders are partly regarded due to an 
affluent society as well 83. The hygiene hypothesis, although revised in the past years, regards 
a modern lifestyle with decreased enteric microbiota diversity responsible for this increase 84. 
Paediatric IBD, also an immune-related disease, has increased during the last decade’s 85. In 
contrast, the prevalence of ap-FGID appears rather stable during the past half century. 
Most studies suggest that RAP in children is associated to lower socioeconomic conditions 86-
88. In contrast, IBS in young adults was more common in those studying at University 
(medical students), as compared to matched controls not at university 86. A large Japanese 
school survey found that consumption of alcohol, smoking, sleep disturbances and anxiety 
was more common in adolescents with IBS 89.  
This thesis has explored he anthroposophic lifestyle in relation to the development of ap-
FGID. We thought that it would be of interest to study the effect of this lifestyle, since diet, 
microbiota and exposure to stress are regarded as contributing etiologic agents in ap-FGID. 
The anthroposophic lifestyle is characterised by differences in diet, for example in 
consumption of lactic acid vegetables and more often a vegetarian, fibre-rich diet 90-92. 
Furthermore, children of anthroposophic families have displayed differences in faecal 
microflora 91, 93, 94. Finally, this lifestyle has also been related to lower cortisol levels in 
  
infants, hypothetically due to lower exposure to external stressors during infancy 95. These 
low cortisol levels predicted a lower risk of sensitisation 96. The anthroposophic lifestyle is 
known to emphasize the importance of protecting infants from unpleasant stressors 97.  
2.2.6 Food 
Both eating and defecation may initiate abdominal pain. Therefore, food has been suggested 
to be the culprit for ap-FGID 98. To study the role of food in the context of ap-FGID is 
difficult, but attempts have been made. Intake of “fast food” was associated to an increased 
prevalence of FGID in a cross-sectional study involving Chinese adolescents, presumably due 
to higher intake of trans-unsaturated fats 99. Primary lactose intolerance depends on an 
inherited absence or reduced capacity of the small intestinal brush border enzyme lactase 100. 
When lactose in milk is not digested by lactase into monosaccharides it acts as substrate for 
colonic bacteria. Common symptoms are abdominal pain, flatulence and watery, acid stools 
upon milk intake. Lactose intolerance is more common in some parts of the world but 
unusual in northern Europe and generally, symptoms are unusual before 5-6 years of age 100. 
Vandenplas has stated that lactose intolerance decreases the quality of life, if not diet is 
reduced in lactose content, but it is not associated with "true disease" 101. The symptoms 
abdominal pain and flatulence in lactose intolerance are considerably similar to those in 
diarrhoea-predominant IBS. A diet low in Fermentable Oligo-, Di- Mono-saccharides And 
Polyol, (FODMAP), reduces both the amount of lactose and wheat. It will be discussed more 
in detail in the Treatment section below. Gluten has become a publicly strong candidate in 
causing abdominal symptoms, and several double-blind placebo-controlled adult studies have 
been performed, with conflicting results 102-104. Wheat, which contains gluten, is one out of 
many short-chain carbohydrates included in the FODMAP concept, but not the single cause 
of IBS. It is important not to confuse gluten sensitivity with celiac disease (CD), and to 
exclude CD before a disoder of non-celiac gluten sensitivity is considered. In children this 
must be emphasised, as CD is a life-long disorder with undebatable benefits of a strict diet. 
Adult patients with gluten sensitivity may decide about the diet for themselves depending on 
symptom intensity. The terms ”non-celiac wheat” or ”wheat protein” sensitivity or 
”FODMAP sensitivity” has been proposed 105. It is reasonable to believe that ap-FGID may 
be falsely regarded as an expression of lactose intolerance or wheat protein sensitivity. Such a 
false diagnosis may be especially frequent in children with diarrhoea-predominant IBS. 
The food content may cause abdominal symptoms, but also eating habits can modify 
gastrointestinal sensation and motility 106. A clear majority of adolescents with IBS have 
reported abdominal symptoms related to eating and that they stop, or restrict eating due to, or 
to prevent symptoms 107.  
2.2.7 Psychological factors and stress 
Psychological and social factors are important in childhood RAP and other health problems 
108, 109. Alfvén et. al. have defined psychosomatic abdominal pain according to the presence of 
predefined criteria. Examples of these criteria are: aggravation of chronic negative stress at 
the time of RAP onset, pain in parallel with chronic negative stress and feeling better or pain-
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free during periods of no negative stress 110. These stressful life events could account for the 
symptoms in nearly half of the children with RAP in their study111. Reduced, as well as 
higher cortisol levels have been shown in children with psychosomatic RAP, indicating a 
dysregulation of the HPA-axis 112, 113.  
In a review on eight prognostic RAP studies, child factors like behavioural disturbances and 
depressive/anxiety disorders were explored in relation to prognosis 114. They found no 
support for the hypothesis that these children factors predicted persistence of RAP. In the 
same review, there was moderate evidence that parental gastrointestinal problems were linked 
to an increased risk of persistence. A more recent prospective study revealed that individuals 
with RAP in childhood had a substantially increased risk of anxiety disorders in adolescence 
and young adulthood 115. 
A key study linked to the expression “Disorders of the Gut Brain Interaction” was performed 
in Australia in a population-based setting on 1002 adults, published in 2012 116. FGID, IBS 
and FD were assessed on one hand and a validated inventory on depression and anxiety on 
the other. With a 12-year follow-up the study showed that FGID at baseline increased the risk 
of depression and anxiety 12 years later. Anxiety at baseline also entailed a small, but 
significantly increased risk of FGID 12 years later, and offers an elegant example that the 
brain-gut pathway in FGIDs is bidirectional 116. An older but smaller study without control 
group, performed in 1996, reveals the possible role of the brain-gut-axis 117. Adult in-patients 
treated for infectious gastroenteritis, thus a selected population at risk for developing post 
infectious IBS, were measured on psychometric scores at the initial illness. Six months later, 
patients who subsequently developed IBS symptoms, had scored higher on anxiety and 
depression at the time of acute infection, than those who did not develop IBS117. 
2.2.8 Exposure to adversities  
 
Retrospective and cross-sectional studies have shown associations between negative life 
events, child abuse, sexual abuse, and abdominal pain 118-121. One prospective study on 
childhood adversity showed no association to IBS at middle-age, but ap-FGID was not 
examined 122. Another prospective study in a subpopulation of children at risk of 
maltreatment showed increased risk of FGID in children after sexual abuse 123. Cross 
sectional and longitudinal studies have suggested that childhood RAP may be associated with 
parental anxiety and depression, most often assessed in mothers 8, 124-127. In a recent study, 
parental pain-threat perceptions seemed to increase number of health care visits for their 
children with RAP 128. 
 
  
 
 
 
2.3 PREVALENCE  
2.3.1 Abdominal pain-related FGID  
In Apley and Naish’s classical study from 1958, the prevalence of RAP was 11 % 11. In the 
most recent review on functional abdominal pain disorders in children, the prevalence ranged 
from 2-31 %, as defined by Apley, Rome II or Rome III 129. The pooled prevalence was 13.5 
%. In a review on 26 FGID studies by Boronat et.al., IBS with a prevalence of 9 %, seemed 
to be the most common presentation of the ap-FGIDs 130. Prevalence has been investigated all 
over the world, with most studies performed in North America and Asia. In recent years, 
studies from Africa (Nigeria) have been published 131, 132.  Boronat et. al. (2017) found no 
evident difference concerning overall prevalence rates over the world 130. Korterink et. al. 
(2015), on the other side, reported higher pooled prevalence rates in South America (16.8 %) 
and Asia (16.5 %) compared to Europe (10.5 %) 129, 130. A large school-based study was 
performed in Japan, but only IBS was assessed with an unexpected high prevalence, 19 %, 
but also a great increase in prevalence rates was seen between 12 and 17 years, from 10 % to 
26 % 89.   
Figure 2. Proc Nutr Soc 2014;73:457-69. Downloaded from https://www.cambridge.org/core. 
Printed with permission. 
20 
 
Prevalence differences between girls and boys were seen already in Apley’s study. In early 
childhood there were similar prevalence rates but from the age of 8 years RAP was 
increasingly common in girls. Later studies also display higher female prevalence rates. Girls 
also more frequently report multiple pain locations, like back-pain, headache and generalised 
pain 133.  
It is difficult to compare the prevalence of RAP both over time and between countries. One 
reason is that definitions have changed during the years, from Apley to Rome IV. 
Nevertheless, percentages are rather stable, not indicating any major fluctuations in the 
prevalence of ap-FGID. With an increase in prematurity and accompanying invasive perinatal 
actions, a rise in the prevalence during childhood could be expected but has not yet appeared. 
The choice of method for measuring, through self-reported questionnaires or parental 
questionnaires, yields different numbers. Parental report most likely underestimates 
prevalence of RAP in adolescents 134. 
Most children with gastrointestinal complaints are diagnosed and treated in primary care 135. 
In studies from Australia and the Netherlands 2-5 % of all paediatric visits in primary care 
were related to abdominal pain 4, 135. In unpublished Swedish data the proportion was similar 
136. In 2012, abdominal pain was the second most common cause for seeking the paediatric 
emergency department at the Karolinska University Hospital in Stockholm (Boston 
Consulting Group, Utredning av framtidens hälso- och sjukvård [Investigation on future 
healthcare] 2012).  
2.3.2 Overall FGID  
In student samples, FGID prevalence ranges from 10-29 %, when defined according to Rome 
II, III or IV criteria 130. The first survey based on Rome IV criteria showed that one out of 
four infants, toddlers, children and adolescents fulfilled symptom-based criteria for a FGID in 
America 40. The study was performed as an online interview with mothers and not on self-
reported symptoms from adolescents.  
 
 
 
 
 
 
 
 
 
  
2.4 TREATMENT 
Developing new tools for treatment of children with ap-FGID is a delicate task. It is often a 
chronic disorder but fluctuating and eventually with long asymptomatic periods. This means 
that the probability that a child with ap-FGID will improve on any treatment is substantial. 
Therefore, it is crucial that research should be performed in randomised, controlled treatment-
studies. Another important issue is the placebo effect. A review on childhood ap-FGID found 
that approximately four out of ten children improve on placebo 137. Furthermore, due to the 
basically benign nature of RAP, treatment should not introduce risks or adverse events. 
The effect of treatment can be measured as pain reduction but also as stooling, number of 
health-care visits, degree of school absence and quality of life. Quality of life has been shown 
to be reduced in children with ap-FGID in many studies 40, 138, 139. It seems reasonable to 
believe that high-quality health care, not necessarily medical investigations, spent on this 
group of patients would create major improvements for both childhood health and health 
economy 6, 7, 9. The physician-patient interaction in IBS is most probably important 140. A 
careful and accurate consultation in children with RAP is also crucial for discovering any 
kind of abuse or maltreatment.   
A few studies have attempted to identify the children with FGIDs who are at greatest risk for 
persistent pain-related impairment 141-143. A major finding was that if both parent and child 
reported presence of clinically significant child anxiety, as compared to discordant reports or 
low anxiety, this was related to an increased future impairment 142. Children without 
relationship between pain and stooling were more prone to a future decreased pain frequency 
143. In the future it may be possible to focus treatment on children at highest risk of 
developing chronic pain and disability.  
2.4.1 Pharmacology 
There is no distinctly evidence based pharmacological treatment in ap-FGID 144, 145. Rather 
often it is difficult to decide if a child with recurrent abdominal pain suffers from constipation 
or IBS. Therefore, the initial treatment of a child with RAP is often laxatives. If pain 
disappears when the child has received accurate laxative treatment, the diagnosis is 
constipation. If pain is diminished but not absent, the diagnosis might be IBS with 
constipation.  
Even if prescribed fibre supplements and bulking agents are not evidence-based for 
treatments of pain in ap-FGID, they seem to be of help for some patients. At least the alliance 
between doctor and patient is improved 146. There is no analgesic treatment that has been 
proved effective in ap-FGID. Antidepressant treatment is often used in adult IBS 147. 
Treatment with antidepressants to patients 6-18 years with IBS has been tried in a few 
randomised trials. The placebo effect was more than 50 %, comparable to treatment with 
amitriptyline 148. In a few small studies, improved quality of life was found in relation to 
antidepressant treatment to IBS, but the treatment had no effects on gastrointestinal 
symptoms. Therefore, antidepressant treatment to young people with IBS should only be used 
in selected cases or in controlled studies.  
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Peppermint oil is a calcium-blocker available in herbal compounds and studied in only one 
randomised controlled study in children 149. The severity of gastrointestinal symptoms was 
significantly more reduced in the peppermint oil treatment group than in placebo. Proton 
pump inhibitors are frequently prescribed to children with ap-FGID 150, but only one 
paediatric study found that another gastric pH-modifying compound, famotidine was 
effective against both reflux disease and functional dyspepsia 151. 
2.4.2 Psychology 
The management of children with ap-FGID often requires an interdisciplinary approach, 
especially in cases with great suffering and frequent school absence 9. Contact with a 
psychologist is sometimes recommended after the diagnosis has been set. Some families 
decline psychiatric or psychological contact and yet others accept but the psychiatric care 
does not always have an effective treatment. Worldwide there are promising psychological 
treatment methods that are investigated scientifically 146, 152, 153.    
 Cognitive behavioural therapy  
Cognitive behavioural treatment (CBT) in ap-FGID can have many different components, for 
example relaxation, cognitive techniques for changing thoughts or distraction 145. CBT can 
also use methods with exposure to gastrointestinal symptoms through exercise involving 
reduced avoidance of activities that induce symptoms 154. CBT in adults with IBS has 
demonstrated considerable efficacy in several studies and is broadly accepted in clinical use 
155. Internet-delivered, exposure-based CBT against ap-FGID has been studied in children 8-
17 years old, with promising results, measured as total score on Gastrointestinal Symptoms 
Rating Scale for IBS 156, 157. A three-session telephone intervention for cognitive behavioural 
therapy with parents proved to be as effective as the same intervention face to face for 
children 7-12 years. Outcomes were parental solicitousness, pain beliefs, catastrophizing, 
child-reported coping and functional disability 158. 
 Hypnotherapy 
Treatment for ap-FGID with hypnotherapy has been subject to several randomised, controlled 
studies in children 159-162. Hypnotherapy to patients with ap-FGID is performed by a trained 
therapist. It includes general relaxation, abdominal pain control and ego-strengthening 
suggestions 161. A protocol adapted for children has been used, with six sessions of 50 
minutes each, during a three-month period. The sessions can be combined with home 
exercises sustained by an audio compact disc. Audio compact disc has also been used 
separately for home treatment 160. Hypnosis by a therapist is expensive and time-consuming, 
and therefore home-hypnosis with the assistance of a compact-disc-player could increase 
accessibility 159.  
Vlieger et. al. performed a randomised controlled study comparing hypnotherapy with 
standard medical treatment in children with FAP or IBS aged 8-18 years. They found a 
reduction in abdominal pain frequency and pain intensity scores, that was significantly 
greater in the hypnotherapy group. At one-year follow-up, successful treatment was 
accomplished in 85 % of the hypnotherapy group and 25 % of the standard medical treatment 
group. Other studies on hypnotherapy to children with FAP and IBS have displayed 
  
improvements in quality of life and reductions in school absenteeism 152. The beneficial 
effects of hypnotherapy have been sustained up to five years after treatment 162. 
2.4.3 Diet  
As mentioned earlier, food is often experienced as the culprit in ap-FGID. Dietary treatment 
of children with ap-FGID should always be performed in cooperation with specially 
educated, paediatric dieticians, with knowledge of the nutritional needs of growing children 
and adolescents. Since many children and adolescents with IBS associate abdominal pain 
with the intake of certain food products, voluntary avoidance is common. Dairy and grains 
are the most commonly avoided foods in children with IBS 163. A limited period of milk 
protein or lactose elimination, in cooperation with a doctor or dietician, may be indicated, 
since the only reliable diagnosis in allergy and food intolerance is elimination and 
provocation.  
The food content can cause intestinal, luminal distension and thereby bloating and pain in 
those with visceral hypersensitivity and abnormal gut motility, which has been shown in IBS. 
Dietary treatments often aim to minimize bacterial fermentation through providing less 
substrate. There are two Cochrane reviews on diet interventions for ap-FGID in children from 
2008 and 2017 respectively 164, 165. In 2008 there were no high-quality studies on the topic. 
Newlove-Delgado et. al. state in 2017 that the evidence for probiotic therapy in IBS is 
moderate, and that there is insufficient evidence for both fibres and FODMAP 164. A low 
FODMAP diet reduces pain in adult IBS but is not enough studied in children 146, 166, 167. It 
has been proposed that the response to diet treatment is dependent on host microbiota, more 
specific the saccharolytic capacity 168. A clinical observation is that children who seek care 
for abdominal pain often associates the pain with certain foods. An interesting study on food 
avoidance found that it was more common in adolescents with IBS than in their healthy 
peers to identify at least one self-perceived food intolerance (92.9 % versus 62.5 %). The 
number of self-perceived food intolerances was weakly associated to severity of IBS 163. 
The first randomised, controlled study on vitamin D supplementation to adolescents with IBS 
was published this year. Subjects were 14-18 years old with IBS according to Rome III and a 
vitamin D level of mean 17.2 ng/ml 169. Vitamin D supplementation improved both 
symptoms and quality of life in subjects with IBS and Vitamin D deficiency, but mechanisms 
are unclear, and results need to be confirmed.  
2.4.4 Probiotics 
A specific dietary treatment is supplementation with probiotics. Probiotics do not require a 
doctor’s prescription and can be administered as pills, capsules, liquids and powders. Foods 
enriched with probiotic bacteria is common in infant formula, yoghurt, cereals etc. 170. 
Probiotics is a concept that has emerged in the last decades and the definition is varying. The 
WHO definition is “live microorganisms which, when administered in adequate amounts, 
confer a health benefit on the host”. Regulations on the number of colony forming units that 
must be included to be called probiotic varies between different countries. It is generally 
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believed that 108 -1010 viable bacteria/day should be administered to be clinically effective 170. 
Common probiotic strains are lactobacillus, bifidobacterium and streptococcus.  
The treatment effects of probiotics are thought to depend on the effects on microbiota, which 
has been described in 2.2.2. Experiments in animals and humans have been able to show that 
the microbiota is altered upon administration of probiotics 52, 171. The mechanism of 
probiotics on gastrointestinal function is conveyed through interference with pathogens, 
improvement of intestinal barrier, immunomodulation and on neurotransmitter production 52, 
171. The treatment of rotavirus-enteritis in children is an example on how probiotic treatment 
can confer health benefits, although the magnitude of effect is moderate 172. 
Treatment with probiotics to children and adolescents with ap-FGID has shown promising 
results. It should be noted that this treatment seems to be free of adverse effects. Randomised, 
controlled studies to children between 4 and 18 years have shown significant improvement in 
frequency and duration of pain as compared to placebo treatment 173, 174. The most consistent 
results have been observed in relation to treatment of IBS and not of FAP or FD. Limitations 
are that the treatment groups have received different probiotic strains and therefore pooling of 
data and meta-analysis are difficult to perform 175. It also worth noting that the required 
duration of treatment is unknown. In clinical trials 4-8 weeks treatment duration is usual 173, 
174.  
Prebiotics are non-digestible carbohydrate fibres, but not as well defined as probiotics. 
Prebiotics are simply food for the probiotic bacteria and interesting as new treatments for ap-
FGID, but not enough studied 176. Food fibres can be regarded as prebiotic.  In the Cochrane 
report on dietary treatment of paediatric IBS, fibre interventions with psyllium, guar gum and 
glucomannan, were compared with placebo. They seemed to improve children with IBS, but 
the quality of these studies was deemed low 164. 
 
 
 
 
 
 
 
 
 
 
 
 
  
3 AIMS 
The overall aim of this thesis was to evaluate a diagnostic questionnaire, to explore risk 
factors and to study prognosis in abdominal pain-related functional gastrointestinal disorders 
in childhood. Specifically, we aimed: 
 
• To evaluate the sensitivity, specificity, and positive predictive value of a Rome 
III-based questionnaire in diagnosing abdominal pain-related functional 
gastrointestinal disorders (ap-FGID) when administered to children seeking care 
for gastrointestinal symptoms (Study I) 
• To explore how alarm symptoms used in different combinations together with the 
Rome III questionnaire affect the sensitivity, specificity, and positive predictive 
value in diagnosing ap-FGID (Study I) 
• To study if overall antibiotic treatment, types of antibiotic substances used, and 
number of antibiotic courses during childhood affects the risk of ap-FGID at 12 
years of age (Study II) 
• To test the hypothesis that family lifestyle is associated with the development of 
ap-FGID at five years of age and to evaluate if any specific lifestyle characteristic 
could explain any such association (Study III) 
• To study if RAP in early childhood or at 12 years of age are risk factors for later 
paediatric RAP or ap-FGID (Study IV) 
• To examine prevalence and turnover of childhood RAP between one and 16 years 
of age (Study IV) 
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4 SUBJECTS AND METHODS 
Paper I was based on a prospective questionnaire validation study performed at paediatric 
outpatient centres and university hospitals. Papers II and IV were performed in the birth 
cohort BAMSE and paper III in the birth cohort ALADDIN.  
4.1 STUDY I. ROME III QUESTIONNAIRE STUDY   
4.1.1 Subjects, inclusion criteria 
We invited 310 children aged 4-17 years to take part in the study. Invited children were 
attending paediatric outpatient centres in Stockholm between January 2013 and May 2014, 
altogether seven centres.  
• A paediatric consultation because of gastrointestinal complaints 
• Signed consent from both parents 
• 83 % of those initially eligible were included in the main analysis, n=258  
4.1.2 Methods 
 Questionnaires 
The sources of data consisted of information from questionnaires at inclusion, data from 
patient records and a diagnostic review. 
• Questions (yes/no) concerning eight gastrointestinal alarm symptoms during the two 
months preceding the visit (Table 4) 
• A validated Swedish version of the Questionnaire on Paediatric Gastrointestinal 
Symptoms Rome III  
• Since three of the alarm symptoms (heredity for organic gastroinestinal disease, 
defecation at night and bloody stools) were associated with organic gastrointestinal 
disease (OGID) in our study, a missing answer on these items excluded the child from 
further analysis. The other five alarm symptoms did not show any significant 
association with OGID and a missing answer on these items was therefore regarded as 
negative 
 Patient records 
Data extraction 6-12 months after inclusion: 
• Number of previous visits for gastrointestinal complaints 
• Specified laboratory tests 
• Diagnostic radiology  
• Endoscopies and bowel biopsy analyses 
• Clinical diagnoses and prescribed treatments 
• Median patient time covered 2.7 years  
 
  
 
 
 
 Diagnostic review  
The most likely clinical diagnosis was set through revision of patient records by two 
experienced paediatric gastroenterologists performed at least 12 months after the study 
inclusion. They were blinded to the answers to the questionnaires. In 249 of 258 cases (97 %) 
there was initial agreement between the two reviewers on whether the cause of 
gastrointestinal complaints had an organic or functional origin. The nine patient records 
where there was initial discordance, were re-reviewed until a common diagnosis was agreed 
upon in all these patients.  
This clinical diagnosis was regarded as the reference when assessing the ability for Rome III 
symptom profiles, alarm symptoms and laboratory tests to discriminate between functional 
and organic causes of gastrointestinal complaints. 
 Statistics 
The capacity of the Rome III symptom criteria to identify abdominal pain-related functional 
gastrointestinal disorders (ap-FGID), alone or in combination with negative alarm symptoms 
or normal laboratory tests, was tested. The reference was the diagnosis set through a record 
review one year after administration of the questionnaire. Sensitivity, specificity, positive and 
negative predictive values were calculated in four field tables.  
The questionnaire answers provided information to classify whether children fulfilled the 
Rome III criteria for ap-FGID, but not for other functional gastrointestinal disorders (FGID), 
for example constipation, vomiting and nausea. Accordingly, the children with a reference 
FGID other than ap-FGID (n=80) were excluded from the main analysis.    
Table 4. ALARM SYMPTOMS 
Heredity for gastrointestinal disease 
Defecation at night 
Bloody stools  
Waking up at night due to abdominal pain  
Right-sided abdominal pain 
Unintentional weight loss  
Painful swallowing  
Unexplained fever 
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The remaining patients were categorised according to three different variables: positive 
paediatric Rome III symptom criteria, negative alarm symptoms and normal laboratory tests 
regarding faecal calprotectin (<100 µg/g) and serum Immunoglobulin-A-transglutaminase 
antibodies (IgA-TGA ab). 
Four different combinations were subsequently compared with the reference diagnosis:  
1) Subjects meeting the positive paediatric Rome III symptom criteria 
2) Subjects meeting criteria in 1) plus negative alarm symptoms  
3) Subjects meeting criteria in 1) plus fecal calprotectin <100 µg/g and normal IgA-TGA 
ab 
4) Subjects meeting criteria in 1) plus both negative alarm symptoms and fecal 
calprotectin <100 µg/g and normal IgA-TGA ab 
 
4.2 STUDY II. BAMSE COHORT 
The BAMSE-project (Swedish acronym for children [Barn], Allergy, Milieu, Stockholm, 
Epidemiology) invited the parents of 7221 new-born children living in urban and suburban 
Stockholm between 1994-1996 to participate in a prospective study 177. The aims of the 
BAMSE project were to establish risk factors for asthma and other allergic diseases in 
childhood, and to study factors of importance for prognosis at already established allergic 
disease. The original cohort comprised of 4089 children, whose parents fulfilled the two-
month-old baseline questionnaire. The follow up rates for parental and child participation 
were 96 % (3925/4089) and 94 % (3843/4089) at 12 and at 24 months respectively. The 
follow up rate for adolescent participation at 12 and 16 years of age were 68 % (2795/4089) 
and 76 % (3115//4089) respectively of the original BAMSE cohort. At 12 and 16 years of age 
it was possible to answer web-based questionnaires. At 12 and 16 years of age adolescents 
and parents answered separate questionnaires.  
4.2.1 Subjects and inclusion criteria 
• The child had answered the question about gastrointestinal symptoms at 12 years  
• No parental report of inflammatory bowel disease (IBD) and/or celiac disease (CD) in 
parental questionnaire at 12 years of age 
• Number of children fulfilling the inclusion criteria, n=2732 
• Flowchart in Figure 3 
 
 
 
 
 
  
 
 
 
 
4.2.2 Methods  
 Antibiotic exposure, questionnaire data  
Information about antibiotic exposure in early childhood was collected from parental 
questionnaires at child ages of 12 and 24 months 178. Children with no parent-reported 
antibiotic use in the first two years of life were considered reference group. Children who had 
received antibiotics were divided into three groups according to antibiotic exposure during:  
• The first but not the second year of life  
• The second but not the first year of life 
• Both the first and the second year of life 
 
Figure 3. Flowchart BAMSE cohort 
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 Antibiotic exposures, The Swedish Prescribed Drug 
Register 
Information about dispensed antibiotics from 9 to 12 years of age was collected through 
record linkage to the Swedish Prescribed Drug Register by using the Swedish personal 
identity number 179. Antibiotics administered in hospital are not recorded in the register.  
Use of antibiotics in the three years preceding the outcome RAP at 12 years of age was 
classified in four different ways:  
• Any antibiotic use in the three years preceding the outcome 
• Number of antibiotic courses: one course, two courses or ≥3 courses  
• Timing of last antibiotic course: up to five months ago, six to 11 months ago or 12 to 
36 months ago 
• Type of antibiotic substance regarding the six most frequently dispensed antibiotics: 
phenoxymetylpenicillin, flukloxacillin, cefadroxil, amoxicillin, erythromycin or 
tetracycline 
 Definition of RAP 
• Children with monthly abdominal pain and no parent-report of doctor’s diagnosis of 
IBD and/or CD before 12 years 
• Post-hoc analyses were performed for weekly abdominal pain with no parent-report 
of doctor’s diagnosis of IBD and/or CD before 12 years 
 Statistics and Confounders 
Multivariable logistic regression analysis was used to assess the risk of RAP at 12 years. 
Confounders were 
• Asthma at one year, defined as at least three episodes of wheeze after three months 
and up to one year of age in combination with treatment with inhaled glucocorticoids 
and/or signs of suspected hyperactivity without concurrent upper respiratory infection 
• Asthma at 12 years, defined as at least four episodes of wheeze in the last 12 months 
or at least one episode of wheeze during the same period, combined with prescription 
of inhaled glucocorticoids for symptoms of asthma   
• Sex 
 
4.3 STUDY III. ALADDIN COHORT 
The ALADDIN birth cohort study (Assessment of Lifestyle and Allergic Disease During 
Infancy) has recruited families at anthroposophic and conventional maternal-child health 
centres 92. The children were followed prospectively from infancy to five years of age, with 
parental questionnaires, clinical visits and biological samplings at regular intervals. Focus in 
the ALADDIN study is to assess development of allergy related disease in children of 
different lifestyles: anthroposophic, partly anthroposophic and non-anthroposophic. In study 
III, children from ALADDINs first recruitment wave (330 families) were supplemented with 
  
140 children from a second wave. This subgroup of 470 children from the cohort were 
recruited in 2004-2009 (Figure 4).    
4.3.1 Subjects and inclusion criteria 
• The parents had completed questionnaire data regarding all items on lifestyle  
• The parents had completed questionnaire data on abdominal pain  
• From the 354 children thus identified, the following children were excluded:  
▪ Children with constipation according to Rome III criteria (n=31) 
▪ Children with infrequent abdominal pain, less than once a week, or 
abdominal pain with a duration shorter than two months (n=131)  
▪ Child with  cow’s milk protein allergy with gastrointestinal symptoms 
(n=1) 
• The remaining study population thus comprised 191 children, who were further 
categorised into three lifestyle groups: non-anthroposophic (n=66) partly 
anthroposophic (n=75) and anthroposophic (n=50) 
 
 
 
 
 Figure 4 Flowchart ALADDIN cohort 
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4.3.2 Methods 
 Questionnaires 
• Lifestyle  categorisations were based on parental responses to four questions: 
1. Had chosen an anthroposophic Maternal and Child health Centre 
2. Had planned anthroposophic child care 
3. At least one parent adhered to an anthroposophic lifestyle 
4. Everyday family life was influenced by an anthroposophic view of life  
Responding yes to all four items was categorised as anthroposophic and no to all 
items as non-anthroposophic. All other alternatives were categorised as partly 
anthroposophic. 
• At child’s age of five years, the parents filled in an adapted Swedish version of the 
Questionnaire on Paediatric Gastrointestinal Symptoms Rome III (QPGS-RIII)   
 Definitions of Irritable bowel syndrome (IBS), Functional 
dyspepsia (FD) and Functional abdominal pain (FAP) 
In all children whose parents stated that the child had abdominal pain at least once every 
week since at least two months a structured telephone interview was performed with one of 
the parents. The following issues were considered: 
• Whether the questionnaire answers could be verified 
• Occurrence of alarm symptoms 
• Previous healthcare contacts  
The main outcome in study III was abdominal pain defined according to the paediatric Rome 
III criteria of IBS, FAP and FD. FD and FAP were analysed together since the only 
difference between them according to Rome III is pain localisation and for children five years 
and younger it is difficult to localise abdominal pain. 
 Lifestyle characteristics  
• Birth (Caesarean section, home delivery) 
• Family characteristics (older siblings, parents born outside Europe, parents with 
University degree and age at child’s birth)  
• Child at two months of age (parents smoke, formula during first week, breastfeeding 
for less than two months, colic, vitamin D supplements, any antibiotic treatment) 
• Child at six months of age (breastfeeding for less than six months, colic, vitamin D 
supplements) 
• Child at 24 months of age (fermented food, vegetarian food, in preschool) 
• Child at five years of age (fermented food, vegetarian food, parent’s divorce, in 
preschool, any antibiotic treatment and number of antibiotic treatments)  
 
  
4.4 STUDY IV. BAMSE COHORT 
The BAMSE-cohort was the basis for study IV (Flowchart Figure 3).  
4.4.1 Subjects and inclusion criteria  
• Parental participation at baseline, child’s age two months 
• Parental participation at 12 or at 24 months of age (at early childhood follow-up) 
• Child participation at 12 years of age (at 12-year follow-up)  
• Child and parental participation at 16 years of age (at 16-year follow-up) 
• Exclusion criterion at early childhood was missing data regarding RAP at either 12 or 
24 months, if combined with no RAP at the other early childhood assessment point 
Multiple assessment points with different follow-up rates were defined: 
• Early childhood, pooled data from questionnaires at 12 and 24 months, 93 % 
(n=3797) 
• At 12 years of age, 68 % (n=2764)   
• At 16 years of age, 74 % (n=3039)   
• Complete follow up at all three assessment points, 60 % (n=2459) 
 
4.4.2 Methods    
 Questionnaires 
• At 12 and 24 months, parents were asked if their child had “repeated attacks of colic” 
during the previous six and 12 months respectively 
• At 12 years, children were asked if they had “recurrent abdominal pain, menstrual 
cramps excluded” and how often it occurred 
• At 16 years, children were asked “How often – in the past two months – have you felt 
pain or discomfort in your stomach?”  
• At 16 years, questions based on the ROME III Questionnaire on Pediatric 
Gastrointestinal Symptoms were included 
 Definitions of RAP, IBS, FD and FAP 
• If parents responded yes that their child had “repeated attacks of colic” either at the 12 
month-questionnaire or at the 24 month-questionnaire, or both, the child was 
classified as having RAP in early childhood  
• Children who had at least weekly abdominal pain with no parent-report of doctor’s 
diagnosis of IBD and/or CD until the time of the questionnaire, were classified as 
having RAP at 12 years 
• Children with at least weekly abdominal pain or discomfort, and no parent-report of 
doctor’s diagnosis of IBD and/or CD in the questionnaires at 12-years and 16-years, 
were classified as having RAP at 16 years 
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• The questionnaire at 16 years allowed us to categorise children affected with ap-FGID 
at 16 years into irritable bowel syndrome (IBS), functional dyspepsia (FD) and 
functional abdominal pain (FAP), all according to the ROME III criteria (Table 2, 
page 10 and Table 3, page 12) 
 Statistics 
• Cross-sectional prevalence estimates were calculated by dividing children with a 
report of RAP or ap-FGID with the total number of children with that information 
available at each respective assessment point  
• The period prevalence was calculated as the proportion of children with at least one 
report of RAP in any of the three assessment points divided by the total number of 
children with any report of RAP or with a consistent negative report at all three 
assessment points, 66 % of original cohort (n=2698)  
• Turnover of RAP was analysed in children with complete follow up at early 
childhood, 12 and 16 years by describing the number of incident cases (no prior 
report of RAP), persistent cases (RAP at two consecutive assessment points) and 
cases in remission (RAP at the previous, but not current assessment point) at each 
assessment point 
• For longitudinal risk estimates we used all observations available 
 Confounders  
• Asthma at one year, defined as in Study II  
• Asthma at 12 years was defined as as in Study II  
• Sex  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5 RESULTS 
5.1 STUDY I  
5.1.1 Questionnaire-based Rome III criteria diagnoses 
The questionnaire-based symptom profile of a functional gastrointestinal disorders (FGID) 
according to Rome III criteria was filled in for 72 % of all study children. One or more alarm 
symptoms were present in 81 % of the participants. Three of the alarm symptoms were 
significantly more common in children with organic gastrointestinal disease (OGID). These 
were heredity for IBD, CD or peptic ulcer disease (p=0.017), defecation at night (p=0.028) 
and blood in stools (p<0.001).   
5.1.2 Patient records 
The mean number of previous visits for abdominal complaints was 1.9 (range 0-5 visits). 
Laboratory testing was performed at least once in most children, including IgA-TGA ab (93 
%), blood counts (92 %) and faecal calprotectin (59 %). Each one of these tests was 
significantly more likely to be normal in children with FGID compared to those with OGID 
(p<0.02). 
5.1.3 Diagnostic review  
FGID was diagnosed in 84 % (216/258). More than half, 54 % of the participants had 
abdominal pain-related FGID (ap-FGID) and in this subgroup of 140 children, 57 had 
irritable bowel syndrome, 59 had functional abdominal pain and 24 were diagnosed with 
functional dyspepsia. OGID was diagnosed in 42 of 258 children (16 %). Inflammatory 
bowel disease (IBD) was diagnosed before entering the study in two children and another five 
were diagnosed after inclusion. Celiac disease (CD) was diagnosed in 18 children. 
Concomitant FGID and OGID was present in nine children, all with celiac disease, and thus 
excluded from all the analyses on FGID. 
5.1.4 Evaluation of Rome III symptom criteria  
The ability of a Rome III-based questionnaire to accurately diagnose an ap-FGID was 
calculated in a four-field table. When using plain positive Rome III symptom criteria for ap-
FGID, the sensitivity was 0.78 and the specificity 0.32. When positive Rome III criteria for 
ap-FGID were combined with the absence of alarm symptoms, the sensitivity was 0.15 and 
specificity 0.90 (Table 5). When positive Rome III criteria for ap-FGID were combined with 
negative IgA-TGA ab and faecal calprotectin <100 µg/g, we found a sensitivity of 0.56 and a 
specificity of 0.85. When positive Rome III criteria for ap-FGID were combined with absent 
alarm symptoms, negative IgA-TGA ab and faecal calprotectin <100 µg/g, we found a 
sensitivity of 0.15 and a specificity of 0.89. We also combined positive Rome III criteria for 
ap-FGID with the absence of only the three alarm symptoms that were significantly 
associated with OGID - heredity, defecation at night and blood in stools. The sensitivity was 
then 0.35 and specificity 0.86. When we included subjects with non-pain-related FGID, 
namely constipation, diarrhoea and vomiting, in the analysis, the sensitivity for plain positive 
Rome III criteria for ap-FGID was 0.78 and the specificity was 0.34.  
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5.2 STUDY II   
5.2.1 Prevalence of antibiotic use and RAP 
According to questionnaire data, 72 % of the children received antibiotic treatment in the first 
two years of life. Antibiotic treatment during the first but not the second year of life occurred 
in 10 % of the children, during the second but not the first year of life in 29 % and during 
both the first and the second year of life in 32 %. In the three years preceding the 12 years of 
age questionnaire, 38 % of the study participants were dispensed a course of a prescribed 
antibiotic drug according to the Swedish Prescribed Drug Register. The mean number of 
dispensed antibiotic courses to all study children during the three-year period was 0.7 (range 
0-83 courses). Of the 1045 children who were dispensed a prescribed antibiotic course in the 
three-year period, 198 (7.3 %) were dispensed three or more courses. The most common 
antibiotic courses dispensed were substances commonly used for treatment of airway related 
diseases such as otitis, tonsillitis, bronchitis and pneumonia. Only 1.5 % of the children were 
dispensed a prescribed broad-spectrum antibiotic from the tetracycline group.  
The prevalence of monthly RAP at 12 years was 9 % and of weekly RAP 4 %. 
5.2.2 Antibiotic use and risk of RAP 
 In early childhood:  
Antibiotic treatment in the first two years of life did not affect the risk of monthly RAP at 12 
years of age in analyses of the whole study group. Stratified analyses showed that girls, but 
Table 5. Functional cause of abdominal pain according to 
questionnaire (Rome III criteria) combined with negative alarm 
symptoms (yes/no) in relation to clinical diagnosis after record 
review (ap-FGID or Organic disease) 
Rome III and negative alarm 
symptoms 
Clinical  
ap-FGID 
Clinical 
organic 
disease 
Total 
Yes 20 4 24 
No 112 36 148 
Total 132 40 172 
Sensitivity: 20/132=0.15  
Specificity: 36/40=0.90  
Positive predictive value: 20/24=0.83 
Negative predictive value: 36/148=0.24  
  
not boys, who received antibiotics during both the first and the second year of life, had an 
increased risk of RAP at 12 years (OR 1.65; 95 % CI: 1.09-2.49). In all other stratified 
analyses, no significant associations were found. 
 Between 9 and 12 years:  
One, two or three antibiotic courses in the three preceding years was not associated with an 
increased risk of monthly RAP at 12 years. In post-hoc analyses three or more antibiotic 
courses in the three preceding years showed an increased risk of weekly RAP (crude OR 
1.97; 95 % CI: 1.12-3.46).  
There was no significant association between any of the examined types of antibiotic 
substances and RAP. However, use of tetracycline was associated with a non-significant 
increased risk of monthly RAP at 12 years of age (OR 1.80; 95 % CI: 0.74-4.34). 
The time between the last dispensed antibiotic course and the outcome questionnaire at 12 
years of age did not affect the risk of RAP. 
Antibiotic use in all the three time periods (0-1 year, 1-2 years and 9-12 years) and RAP at 12 
years of age showed no association (OR 1.03; 95 % CI: 0.70-1.54).  
 
5.3 STUDY III  
5.3.1 Prevalence of ap-FGID 
The prevalence of ap-FGID at five years was 15 % (54/354) in the total ALADDIN cohort. 
IBS was present in In most cases the duration was more than one year. Of the 191 children 
who were selected for analyses in relation to their lifestyle, 17 % had ap-FGID in the non-
anthroposophic lifestyle study group, 33 % in the partly anthroposophic group and 36 % in 
the anthroposophic group.   
5.3.2 Risk of ap-FGID depending on lifestyle 
Growing up in families with a partly anthroposophic lifestyle was associated with a higher 
prevalence of abdominal pain at five years of age, compared with growing up in a non-
anthroposophic family (adjusted OR 2.61; 95 % CI: 1.15-5.93). In the post-hoc analysis we 
also calculated the corresponding odds ratio for the 125 children in families with any 
anthroposophic lifestyle characteristic, grouping both anthroposophic and partly 
anthroposophic families together. Growing up in families with any anthroposophic lifestyle 
was associated with a higher prevalence of abdominal pain at five years of age, compared 
with growing up in a non-anthroposophic family (adjusted OR 2.50; 95 % CI: 1.17-5.32). 
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5.4 STUDY IV 
5.4.1 Prevalence of RAP 
Prevalence of weekly RAP in early childhood, at 12 years of age and at 16 years of age, were 
7 %, 4 % and 20 % respectively. In total, 33 % of all children reported RAP at least once 
during the follow up. The prevalence of RAP peeked at 16 years of age in both boys and 
girls. Prevalence estimates were significantly higher for girls compared to boys at 12 and at 
16 years of age but not in early childhood. 
5.4.2 Prevalence of ap-FGID and phenotype distribution 
In the cohort at 16 years, 20 % (609/3039) had RAP and out of the 609 adolescents with RAP 
498 answered the detailed Rome III questions that enabled classification of ap-FGID 
subtypes. In 348/498 the Rome III criteria for any ap-FGID were fulfilled. In this subgroup, 
IBS was found in 6.0 % (175/2926), FAP in 3.4 % (99/2926), FD in 2.7 % (79/2926) and 
overlapping IBS and FD in 0.2 % (5/2926). The prevalence of ap-FGID was higher in girls 
than in boys (16 % vs 8 %, p<0.01).   
5.4.3 Turnover  
Complaints of RAP over two assessment points was reported in 2.8 % (70/2459) of the 
children, 77 % of them being girls, and complaints over three assessment points was reported 
in four children, all girls. Children with RAP in early childhood and at 12 years of age 
reported persisting symptoms at the following assessment point in 7 % and 43 % of cases 
respectively. It was more common for girls than for boys to report persisting symptoms 
between early childhood and 12 years, but not between 12 years and 16 years.    
5.4.4 Risk of persistent RAP during childhood   
There was no statistically significant association between RAP in early childhood and at 12 
years of age (adjusted RR 1.7; 95 % CI: 0.9-3.0). (Figure 5). Children with RAP at 12 years 
of age had an increased risk for RAP at 16 years of age (RR 2.1; 95 % CI: 1.79-2.73) for any 
ap-FGID at 16 years of age (RR 2.5; 95 % CI: 1.8-3.4) and for IBS at 16 years of age (RR 
3.2; 95 % CI: 2.0-5.0). All analyses were adjusted for sex. 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Sex-adjusted associations of RAP and Rome III ap-FGIDs and IBS at 16 years by 
exposure to RAP earlier in childhood in a population-based birth cohort 
Total number observations used (listed in the order they appear in the forest plot from top to 
bottom): 2689; 2927; 2820; 2820; 2524; 2441; 2441 
Associations assessed in a binominal generalized linear model with log link 
Error bars represent 95% confidence intervals 
Early childhood includes children 12-24 months of age, and RAP was parent-reported 
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6 ETHICAL CONSIDERATIONS 
 
All studies in this thesis were approved by the Regional Ethics Review board in Stockholm. 
No pharmacological interventions were performed in any of the studies. In study I, the   
information about the study was addressed to both parent and child at the doctor’s visit, 
adapted to the child’s age and maturity. Written parental consent was required from both 
when there were two caregivers. Personal data (name, social security number) were kept 
separate from study data. The principal investigator kept the code keys, but the identity of the 
study persons was available to the researchers on request. 
In the BAMSE and ALADDIN study, parents were recruited and signed informed consent 
starting in 1994 and 2002 respectively. In follow-up at 12 years in BAMSE, an information 
letter was sent to the parents with a request to show it to the child. A completed questionnaire 
was regarded as consent from the 12-year-old adolescent in BAMSE study and at inclusion in 
study I.  
The ethical issues of this research are about asking people questions, about registries and of 
reading patient records in another purpose than health care. All studies involved parent and 
/or patient questionnaires, and these could be extensive, requiring time, energy and 
consideration to fulfil. We must also consider how the questions asked to participants may 
affect them. Participants may understand what associations we intend to explore, also when 
we don’t express them clearly. We may simply put ideas in somebody’s head, by introducing 
beliefs on false associations, long before the study results are ready. 
In the recruitment of patients for study I, my personal experience was that when a patient was 
a potential study participant and I knew that the record could be reviewed, this could sharpen 
the consultation. Eventually the patient record writing became more structured, knowing that 
it could be part of research. It is good for research purposes and for the patient, if the doctor is 
precise and thorough in the documentation process.  
In study III, I made phone calls to parents to confirm questionnaire answers that their child 
had abdominal pain at least once a week during at least two months. One of the most 
important ethical issues is that research must not do harm to participants, but in some phone 
calls I got the impression that my call and questions induced worry, as if the parent got the 
feeling of having failed to seek health care for the child with abdominal pain. In these 
situations, I provided more information on ap-FGID and its high prevalence.    
 
 
 
 
  
7  DISCUSSION  
7.1 DIAGNOSING AP-FGID, STUDY I  
In study I we explored if abdominal pain-related functional gastrointestinal disorders (ap-
FGID) could be diagnosed with patient- and parent-administered questionnaires based on the 
Rome III criteria, together with absence of a selection of alarm symptoms. The questionnaire 
answers regarding Rome III criteria alone could predict ap-FGID with low to moderate 
accuracy. With addition of alarm symptoms to the questionnaire-based Rome III diagnosis, 
the specificity for a functional diagnosis was high, but sensitivity was low. If questionnaires 
based on Rome III-criteria together with absence of alarm symptoms were used clinically, 
85% of the children in the study who were finally diagnosed with ap-FGID had needed 
further investigations. It is doubtful if that would have been ethically advisable. In all children 
with a symptom profile of ap-FGID according to Rome III and negative alarm symptoms, 17 
% would have an organic diagnose according to our study.  
The study did not include follow-up questionnaires, so there could be one year between the 
two time points: 1) when the Rome III questionnaire was answered and 2) when the reference 
diagnose was set through record review. Symptom development in this time frame is 
plausible and is often a clinically useful tool. In 2005 a review of 94 articles on chronic 
abdominal pain in children rated the diagnostic value of alarm symptoms as lowest level of 
evidence 1.  Some years later the first comparisons and validations of alarm symptoms or red 
flags in ap-FGID were published 25, 180. In the update on Rome IV criteria, 13 potential alarm 
features were listed. The note says that ‘a clinical judgment should be exercised, putting what 
might be considered an alarm sign into the whole context of the history and physical 
examination’. Between Rome III and Rome IV, the alarm sign ‘pain that wakes the child 
from sleep’ has been removed, replaced by ‘nocturnal diarrhoea’. In study I, the alarm sign 
of nightly awakening due to pain was not included but the sign that was asked for: ‘waking 
up because of defecation at night’ was significantly associated to OGID. Thus, our study 
seems to have chosen a more valid alarm sign than those postulated in Rome III, resembling 
the modified alarm sign in Rome IV. A new alarm sign was added in Rome IV, odynophagia, 
which is specific for eosinophilic esophagitis, an increasing entity in paediatric 
gastroenterology 181. We included seven of the 13 potential Rome IV alarm signs and found 
three of them to be significantly associated with OGID: family history of organic 
gastrointestinal disease, rectal bleeding and defecation at night. In summary, alarm symptoms 
for organic disease in children with ap-FGID is a field with scarce knowledge and a large 
need for more validation studies. 
Study I is an observational study with prospectively collected data. A major strength is the 
detailed description of performed analyses and investigations in children seeking care for 
potential ap-FGID, and the long follow-up in records of previous health-care contacts in 
children with functional gastrointestinal disorders (FGID). This was possible thanks to the 
digital patient records.  
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The limitations of study I depend on factors often associated with studies performed in 
clinical settings. We had to balance between power (best possible participant recruitment) and 
strict inclusion criteria. We excluded 80 participants who had a FGID (and not an ap-FGID) 
but in the validation analyses inclusion or exclusion of these 80 participants hardly affected 
the results. To enable inclusion at different sites and by many different nurses and doctors, we 
decided to ask patients for participation when clinically possible. This may have introduced a 
selection of participants. Children / adolescents with long and complicated complaints may 
not have been invited because the staff thought it cumbersome for a family already in great 
suffering. According to the referral routines at the Hospital in question, patients with a high 
suspicion of inflammatory bowel disease (IBD) or celiac disease (CD) are directed for 
endoscopy without a previous outpatient visit. In the actual sample the number of children 
with OGID is lower than expected, which may have decreased the generalisability of the 
study. Generalisability could have been improved if all children with a consultation because 
of gastrointestinal complaints at the recruiting centres had been included, and if those who 
declined to participate had been possible to characterise and compare to those included. 
 
7.2 RISK FACTORS 
STUDY II and III explores risk factors for ap-FGID in childhood, using two different birth 
cohorts. Research on risk factors of a disorder is especially interesting when the association is 
strong, and you can minimise the risk of disease by eliminating the risk factors but 
identifying risk factors can also lead to important clues about disease and pathogenic 
mechanisms. When mechanisms are elucidated, the possibilities of developing effective 
treatment are improved. 
7.2.1 Antibiotic treatment, Study II 
In study II we investigated antibiotic exposure in relation to RAP at 12 years of age. We did 
not find a statistically significant associations between antibiotic use and monthly RAP at 12 
years. The large, population based, prospective BAMSE cohort with small loss-to-follow-up 
is a major strength of study II. Insufficient statistical power may always introduce a risk of 
not detecting associations. This possibility must be considered also in large studies like this 
one. Thus, we cannot exclude that a larger sample size would have found an association 
between antibiotic treatment and RAP. For instance, we found that three or more courses of 
antibiotics were almost significantly associated with a 50 % higher prevalence of monthly 
RAP (OR 1.54, 95 % CI: 0.99-2.49). Moreover, in the subgroup of 40 children who were 
exposed to tetracycline treatment, six children had RAP at 12 years and the OR of monthly 
RAP at 12 years was 1.80 (95 % CI: 0.74-4.34).  
The Swedish Prescribed Drug Register is a highly reliable source with the limitation that it 
did not start until 2005, and that it registers dispensed drugs, not used drugs 182.  
It is a limitation that the design of the questionnaires did not allow us to use definitions 
according to Rome III criteria at 12 years. The definition of RAP in Study II applied to 
  
Apley’s with monthly abdominal pain. By adding post-hoc analysis of weekly abdominal 
pain, the comparability to Rome III was made easier. No major differences in the risk of RAP 
were revealed with the outcome of weekly RAP.  
Since a parental risk factor for children’s RAP is anxiety, this trait might increase the 
probability of a doctor’s visits of any cause. Consequently, children with an anxious parent 
may seek a doctor more often, and a doctor’s visit per se may hypothetically increase the risk 
of antibiotic treatment. Theoretically, children with increased risk of RAP may have received 
more antibiotics, thereby introducing a kind of confounding by indication. This could 
theoretically have increased the ORs in the study. The exclusion of 20 children with CD and 
IBD in Study II could be questioned, since these participants were not excluded in Study IV, 
but there classified as non-RAP. At least IBD patients should stay excluded in Study II, since 
they are often treated with antibiotics and would introduce differential misclassification. CD 
patients could have been kept but due to the small number it would probably not have 
affected the result.   
Due to the population-based design and relatively high follow-up rates, the generalisability of 
results is deemed high. 
7.2.2 Lifestyle, Study III  
Lifestyle characteristics as risk factors were explored in Study III. No single characteristic of 
the anthroposophic lifestyle could be identified as a risk factor but taken together, this 
lifestyle was associated with an increased risk of ap-FGID at five years of age. Several 
possible factors of the anthroposophic lifestyle were candidates for this increased risk of ap-
FGID. For example, consumption of fermented food and less antibiotic use thereby 
modifying microbiota, and a vegetarian diet through a higher fibre content. Starting pre-
school at an older age could affect several psychological factors including coping strategies. 
Having two or more older siblings was more common in anthroposophic families but also 
independently associated to ap-FGID. Sibling rivalry was predictive of non-organic cause of 
abdominal pain in an Indian study but having older siblings has not been studied 183.  
Inversely, Alfvén found jealousy towards younger sibling in two cases of psychosomatic 
abdominal pain 111.  
Previous research on the influence of socioeconomic factors and educational level on ap-
FGID is contradictory. In paediatric studies economic stress and lower socioeconomic 
stability, has been associated to an increased risk of ap-FGID, while adult irritable bowel 
syndrome (IBS) has been linked to a higher education and childhood affluence 87, 88, 184, 185. A 
recent meta-analysis showed no relation between IBS prevalence and national socioeconomic 
status, but there are no similar surveys on the wider concept of ap-FGID 186. A plausible 
explanation of the two-fold increased risk of ap-FGID in five-year olds of anthroposophic 
families is the impact of exposure to (adverse) life events. Psychological research indicates 
that a moderate number of adverse events are beneficial, when compared to a history of none 
or repeated adverse events 187-189. A characteristic of the anthroposophic lifestyle is parental 
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ambitions to protect their children from unpleasant external stressors, and this is suggestive to 
account for the lower evening salivary cortisol levels in their offspring 97 190. Differences 
between anthroposophic versus non-anthroposophic parents concerning stress management 
are probably most pronounced in everyday life. For example, variations in the number of 
daily activities and new situations the infant meets in early life, at what age they start day-
care and for how many hours. We hypothesize that infants of anthroposophic families are less 
exposed to new or strange situations, thereby getting less exercise in coping with what is new 
and different, for example sensations from the gastrointestinal canal. The generation R study 
performed Strange Situation Procedures in 14-month-old infants, to assess their ability to 
cope with stress and linked it to salivary cortisol levels 191. Cortisol stress reactivity when left 
alone with a stranger was slightly, but not significantly higher in infants with abdominal pain 
than in those without. Another very important experiment has been performed on children 8-
16 years of age with RAP and healthy controls192. Parents were randomly assigned three 
different instructions on how to deal and react to their child’s experimentally induced pain: 
attention, distraction, or no instruction. Both in RAP-patients and well children parental 
distraction gave the lowest pain scores in response to the experimental pain 192. Parent 
attention reinforced the child’s pain in both groups, but the effect size was larger in pain 
patients and more pronounced in females.  
A strength of study III is that the definition of ap-FGID adheres to Rome III criteria and that 
children with constipation or minor abdominal pain could be identified. The relatively small 
sample size entailed a risk of type II-error, but nevertheless we could detect a significantly 
increased risk of ap-FGID in children of anthroposophic families.  
A limitation is the lack of information on parental ap-FGID since it might be a potential 
confounder. Genetic or social trait in ap-FGID has been explored, but only in a few studies 39-
41. The children of our study may have had an increased hereditary risk of ap-FGID. Parents 
who choose to live according to the anthroposophic lifestyle could have chosen it due to 
susceptibility to stress and even be more prone to disorders where stress is thought to be 
involved, like IBS. If a hypothetical scenario with a higher prevalence of parental ap-FGID is 
correct, the increased risk we found in children of these families could be attributed to 
selection bias. Another possible but opposite scenario is that these parents have improved 
skills in dealing with environmental stress, and that their children might have displayed an 
even higher prevalence of ap-FGID without their parents’ capacity in stress coping. 
The families in the ALADDIN cohort were considered representative of the residential area. 
The non-anthroposophic families are considered representative of the general population 
since prevalence of traditional risk factors of allergy was similar to the larger BAMSE study 
193. The generalisability is therefore regarded as reasonably high. 
 
  
7.3 PROGNOSIS, STUDY IV 
In study IV the prognosis of RAP was explored, from the age of 12 months to 16 years of 
age. RAP is a chronic disorder with an intermittent character. The prognosis is important for 
the patient, the parents and the doctor. Two large, population-based, longitudinal, prospective 
birth cohort studies on prognosis have been performed with 29 years and 26 years of follow-
up, respectively 8, 194. British children with persistent RAP on three measurements in 
childhood, at 7, 11 and 15 years were evaluated for physical symptoms and psychiatric 
disorders at age 36 years. The main finding was that the children with RAP in childhood had 
a doubled risk of an emotional disorder, and no increased risk of a physical disorder when 
controlling for psychiatric disease 8. In the Australian study, a moderately increased risk of 
adult IBS, defined according to Manning, was observed in adults who had a history of RAP at 
7-9 years of age 194. 
The association between infant colic and RAP is not well explored. Canivet found that ex-
colicky children displayed more negative emotions and stomach pain at 4 years of age, 
although stomach pain was not strictly defined 195. Ramchandani et. al. found a considerably 
increased risk of persistence from two years of age up to school-age 196. This finding of 
persistent RAP was not confirmed in study IV. Other studies have focused on influence of 
RAP-associated symptoms, like headache, limb ache and back-pain. For example, Walker et. 
al. showed that children with ap-FGID in combination with non-abdominal pain(s) had a 
doubled risk of persistent ap-FGID 10 years later 197. In a review by Gieteling et. al., parental 
gastrointestinal problems were a risk factor for RAP persistence 114.    
The strengths of study IV are similar to study II, namely the large BAMSE cohort and an 
even better follow-up rate at 16 years than at 12 years plus the Rome III defined ap-FGID at 
16 years. As in all questionnaire studies, there is a risk of recall bias. Parents answering 
questions on RAP in the preceding 6 months when child is 12 and 24 months probably have a 
better memory if RAP was difficult and long-lasting, which will underestimate the prevalence 
at these ages.  
 
7.4 GENERAL DISCUSSION 
This thesis is based on four prospective studies aimed to elucidate the large clinical entity of 
RAP and ap-FGID in childhood. Recurrent abdominal pain in children is recognized in 
science as a frequent and troublesome disorder in childhood since more than 60 years 11, 198. 
The current perspective is biopsychosocial, and the cause is regarded multifactorial.   
This thesis showed that one third of Swedish children between one and 16 years experiences 
RAP. In an individual perspective, i.e. the parent who seeks health-care for their child, the 
most important is to exclude that the child has an organic disease. In a social and economic 
perspective, it appears equally essential to improve diagnostics and treatment of children with 
ap-FGID. The future dealing with the pain in the family is influenced by many factors. It can 
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be hypothesised that one factor is the quality of the consultation. Were the family’s questions 
addressed? Medical consultations are improved by asking about the patient’s expectations, 
fears and imaginations about disease, and most likely this is true also in the context of ap-
FGID 199. Anxiety in parent and child is associated to RAP. Abdominal pain and anxiety can 
both be serious and debilitating conditions and must be taken seriously when dealing with 
this group of patients. Consultation and trust seems to be the way to success, where repeated 
visits to the same doctor is a useful tool 5.  
Chrushell et. al. has shown that the prognosis is poorer for a child with RAP whose parents 
consider/believe in an organic origin of pain200. Parents’ beliefs are probably affected by 
several factors both within health-care and outside the control of doctors and other 
professionals. RAP in children can be chronic, very often relapsing and in a group of 
children, regardless what actions are taken, there will be repeated doctor’s visits over many 
years.  
The prognosis study showed that the general prognosis of RAP is good, and that most 
children with RAP grow out of it. All the same, having RAP increases the risk of future RAP, 
ap-FGID and IBS. The knowledge that RAP usually is a transient disorder is a very important 
message for paediatricians and generalists to worried children and parents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
8   CONCLUSIONS 
 
• A Rome III-based patient-administered questionnaire to children seeking care for 
gastrointestinal symptoms had low to moderate sensitivity, specificity and 
positive predictive value in predicting an ap-FGID diagnosis, based on a record 
review one year after the questionnaire was filled in 
• When adding a prerequisite of negative alarm symptoms to the Rome III 
questionnaires, specificity became high but due to low sensitivty, very few 
children could be diagnosed with ap-FGID  
• Antibiotic treatment in childhood was not a major risk factor for RAP 
• Children growing up in a family with an anthroposophically inspired lifestyle had 
an increased risk of IBS, FD and FAP at five years of age 
• Most children with RAP in early childhood or at 12 years of age do not have 
persistent paediatric RAP 
• RAP at 12 years was an independent risk factor for RAP at 16 years of age 
• One of three children had RAP at least once between one and 16 years of age 
 
9    FUTURE PERSPECTIVES 
The international research in paediatric FGID is extensive but not in relation to its prevalence. 
Probably, studies on psychological and dietary treatment will increase.  
Other targets that would be interesting to address is the doctor’s worries in managing children 
with RAP. If the doctor is worried it will remain hard to comfort the family. Could this be 
altered by team-work and peer mentorship? 
Alarm symptoms in ap-FGID need more scientific attention. It would be interesting to study 
if a selection of suggested alarm symptoms could improve diagnostic efficacy, certainly if 
asked and evaluated by the doctor and not in a patient-administered questionnaire. Further, it 
would be interesting to study health care seeking, and if children with ap-FGID and their 
parents who seek medical advice are different from those who do not. Children with ap-FGID 
who seek health care, do they have more alarm symptoms than children with ap-FGID not 
seeking health care?  
 
 
  
10    SAMMANFATTNING PÅ SVENSKA 
Det är mycket vanligt att barn har återkommande magont (eng: Recurrent Abdominal Pain 
RAP). Den polade prevalensen i studier från hela världen är 13,5 %. Med återkommande 
menas att barnet besväras regelbundet under minst 2–3 månaders tid. Orsakerna är många och 
kan vara organiska/medicinska eller funktionella. Exempel på medicinska orsaker är 
inflammatorisk tarmsjukdom och celiaki. De funktionella orsakerna definieras utifrån 
symptom. Det finns ingen provtagning som kan bekräfta att RAP beror på funktionell 
magtarmsjukdom (FMT). FMT definieras för både barn och vuxna enligt internationellt 
accepterade kriterier, de s.k. Rom-kriterierna. Rom-kriterierna för barn kom 1999 och har 
uppdaterats 2006 och 2016 och indelas i smärt-dominerade och icke-smärtdominerade FMT. 
De smärtdominerade FMT enligt Rom III innebär magont minst en gång i veckan under 
minst två månader i följd. Irritabel tarm, funktionell dyspepsi och ospecificerad funktionell 
buksmärta är de tre smärtdominerade FMT. Bukmigrän hör till denna grupp men har 
annorlunda frekvens och duration och undersöks inte i denna avhandling. 
Orsaken till funktionell magtarmsjukdom betraktas som multifaktoriell, dvs orsakerna är 
många och sammansatta. De bidragande faktorer som forskning kunnat identifiera är 
associerade med ärftlighet, tarmfloran, inflammation, förändrad tarmrörlighet och 
smärtupplevelse, kost samt psykologiska faktorer som traumatiska upplevelser, depression 
och ångest. ”Gut brain-axis” är ett centralt begrepp, och innebär att smärtan vid funktionell 
magtarmsjukdom anses bero på ett samspel mellan hjärnan och magtarmkanalen. Tarmen är 
försedd med ett utbrett nervsystem och av ett immunologiskt aktivt system. Interaktionen 
anses medföra att tarm och hjärna påverkar varandra i båda riktningar.  
Möjligheten till läkemedelsbehandling vid FMT är ytterst begränsad. Ett biopsykosocialt 
synsätt anses mest framgångsrikt vid behandling av FMT hos barn. Det betyder att man vid 
behandling behöver ta hänsyn till både biologiska system, psykologiska och sociala faktorer. 
Patient-läkar-relationen är av stor betydelse när det gäller information och lugnande besked 
till patient och föräldrar. Det pågår mycket forskning inom psykologisk behandling, t.ex. 
kognitiv beteendeterapi och i bland annat Nederländerna har man studerat hypnos till barn 
med FMT med goda resultat. Försök med kostbehandling syftar oftast till att minska intag av 
jäsningsbara kolhydrater, vilka anses kunna bidra till smärta vid FMT. Det pågår sådana 
studier hos barn, men det är viktigt att de är dubbel-blint utförda med placebo-kontroll. Vid 
kostbehandling till barn är det väsentligt att försäkra sig om att det inte försämrar intaget av 
energi och näringsämnen för en växande individ. 
 
Syftet med denna avhandling var att kartlägga riskfaktorer för FMT hos barn, att studera hur 
tillgängliga diagnosmetoder fungerar och att studera prognosen för barn med FMT. 
Denna avhandling bidrar till ökad kunskap om FMT hos barn genom dessa fynd: 
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➢ De diagnosmetoder som finns tillgängliga genom frågeformulär från Rom-kommitten 
är måttligt bra på att ställa diagnosen FMT. Det innebär att om dagens 
diagnosformulär och alarmsymptom användes i diagnostiken skulle 85 % av barnen 
med FMT vara tvungna att genomgå ytterligare kanske smärtsamma procedurer utan 
att det ger någon mer användbar information 
➢ Dessa frågeformulär är bra på att utesluta att magont inte beror på organisk sjukdom, 
men bara hos en liten andel av de som har återkommande magont 
➢ Antibiotikabehandling, som anses vara en riskfaktor för vuxna med FMT, ökade inte 
risken för FMT hos barn som behandlats 
➢ Barn i familjer med en delvis antroposofisk livsstil hade en ökad risk för FMT vid 
fem års ålder 
➢ Den antroposofiska livsstilen innehåller flera faktorer som skulle kunna förklara 
denna skillnad, men vi fann ingen enskild faktor i vår studie som stod för 
riskökningen 
➢ Barn som har återkommande magont (RAP) vid två respekiver 12 års ålder har det 
oftast inte vid uppföljning vid 12 eller 16 års ålder. RAP vid 12 år är ändå en 
riskfaktor för RAP vid 16 år  
➢ Cirka en tredjedel av svenska barn har återkommande magont någon gång mellan ett 
och 16 års ålder 
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